Studies of patients followed up by the Signatera test have been published in the best-known international journals with respect to the most common solid tumours (colon, breast, lung) and the hard-to-diagnose bladder tumour. [2-5].
2. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.
3. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019. doi:10.1001/ jamaoncol. 2019.05282. [Epub ahead of print]
4. Christensen E, Birkenskamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic ecacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019. doi: 10.1200/JCO.18.02052. [Epub ahead of print]
5. Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-3663. [Epub ahead of print]